Loading... Please wait...

Our Newsletter

Ambrisentan | Endothelin receptor type A/ETa antagonist

  • Ambrisentan.jpg
  • Ambrisentan, 400x400px, png
Catalog #:

Product Description

Ambrisentan is a propanoic acid??based, orally-available, endothelin receptor type A-receptor antagonist for the once-daily treatment of pulmonary arterial hypertension (PAH). It has >4000-fold selectivity for the type A receptor over type B receptor. Studies indicate that Ambrisentan has a low potential for drug interactions and at therapeutic concentrations does not inhibit UDP-glucuronosyltransferases or CYPs, or induce MDR protein 2 or P-gp. (1)

In contrast with other similar therapies, Ambrisentan has been shown to have a lower potential for increase of serum-level concentrations of aminotransferases. (2)

Technical information:

Chemical Formula:   C22H22N2O4
CAS #:   177036-94-1
Molecular Weight:   378.42
Purity:   > 98%
Appearance:   white
Chemical Name:   (S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid
Solubility:   Up to 100 mM in DMSO
Synonyms:   LU-208075, BSF-208075

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Frampton, JE., Ambrisentan. Am. J. Cardiovasc. Drugs 2011, 11(4), 215-226. Pubmed ID: 21623643
2. Galie et al., Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation, 2008, 117, 3010-3019. Pubmed ID: 18506008

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the Ambrisentan | Endothelin receptor type A/ETa antagonist to your wish list.

You Recently Viewed...